^
Association details:
| Biomarker: | FRS2 amplification + MDM2 amplification |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Kisqali (ribociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
Published date:
09/04/2023
Excerpt:
Patients with co-amplified FRS2/MDM2 exhibited a greater reduction in disease progression with ribociclib vs placebo (HR, 0.23 [95% CI, 0.11-0.51], P=0.0255)…Median PFS in patients with altered BRCA1/2 was 14.6 months with ribociclib and 8.1 months with placebo...This analysis identified biomarkers that may be associated with of response or resistance to ribociclib that could affect future drug development for patients with ABC.
DOI:
https://doi.org/10.1016/j.annonc.2023.08.011
